S&P/ASX All Ords Index (ASX: XAO) shares are down 1.6% to 8,961.6 points on Thursday.
Meanwhile, on The Bull, three experts give us their views on three ASX All Ords shares.
Let's check them out.
Image source: Getty Images
Saluda Medical Inc (ASX: SLD)
The Saluda Medical share price is 40 cents, down 3.7% today and down 69% over 12 months.
Stuart Bromley from Medallion Financial Group has a buy call on this ASX All Ords healthcare share.
Bromley said:
Saluda makes the Evoke spinal cord stimulator, which automatically adjusts pain therapy in real time.
Results in full year 2026 were strong, in our view. Revenue of $US90.2 million was up 28 per cent on the prior corresponding period and ahead of upgraded guidance. US patient implants increased by 50 per cent in the fourth quarter of 2026.
With its newly approved CAP24 surgical paddle lead expanding the addressable US market by about 30 per cent, we believe SLD presents as an attractive buying opportunity for investors comfortable with potential share price volatility and risk.
Generation Development Group Ltd (ASX: GDG)
The Generation Development share price is $3.12, down 2.5% today and down 51% over 12 months.
Bromley has a hold rating on this ASX 200 financial share.
He said:
GDG operates a portfolio of growing financial services businesses, including Generation Life, Evidentia Group and Lonsec.
Total revenue of $178.7 million in full year 2026 was up 23 per cent on the prior corresponding period.
Underlying net profit after tax of $40.7 million grew 21 per cent, supported by growth of 37 per cent in funds under management and record group net inflows of $9.7 billion.
We believe GDG's longer term growth opportunity remains intact.
Fletcher Building Ltd (ASX: FBU)
The Fletcher Building share price is $3.04, down 2.3% today and up 9% over 12 months.
Mark Elzayed from Vestra Capital has a sell rating on this ASX 200 industrials share.
Elzayed said:
The return to profitability reflected a combination of cost reductions, portfolio simplification, property sale gains and an improved performance across several core manufacturing businesses, rather than a broad based recovery in underlying construction demand.
Revenue of $NZ5.994 billion from continuing operations increased 7.3 per cent in full year 2026 when compared to the prior corresponding period.
Total net earnings attributable to shareholders reached $NZ228 million, compared to a loss of $NZ419 million in the prior year.
The return to profitability improves the balance sheet and reduces financial risk. But, in my view, a continuing recovery remains heavily dependent on building markets returning to normal in what I consider a most challenging underlying environment.
